April 19th 2024
Results published in the journal Ophthalmology find no risk reduction from daily one-gram capsules of omega-3 fatty acids.
New Study Planned for Bevacizumab to Treat AMD
December 20th 2023Outlook Therapeutics plans to begin a study in the first quarter of 2024 to address the issues identified in a FDA complete response letter. If approved, Lytenava would be the only bevacizumab product to specifically treat age-related macular degeneration.
Read More
Independent Assessment of Syfovre Needed, Argues JAMA Ophthalmologist Viewpoint
December 7th 2023A California retinal specialist argues in a JAMA Ophthalmology viewpoint article that an independent panel of retinal specialists and statisticians should assess the data from clinical trials of Syfovre (pegcetacoplan) because of the lack of a complete FDA scientific analysis of the drug and of peer-reviewed publication.
Read More
The authors of a case series reported in today's edition of JAMA Ophthalmology say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters. Of the 55 patients treated with Syfovre, 16 developed floaters.
Read More
A New Stem Cell Approach Offers Hope for Those with Chemical Eye Burns
August 31st 2023Researchers at Mass Eye and Ear and Dana-Farber Cancer Institute have developed a new technique for growing stem cells harvested from the eye that meets the FDA’s regulatory requirements for tissue engineering.
Read More
Less than 3% of cataract surgery patients received the sustained-released corticosteroids. The authors argue that the price of more than $500 is an unintentional consequence of rules that require relatively high prices to meet the thresholds for the cost of the news drugs to be passed through to the Medicare program.
Read More